Non-squamous non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Kyoto Prefectural University of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Non-squamous cell non-small cell lung cancer confirmed by histology or cytology. (2) Clinical stage IIIB, IIIC, IVA, IVB* or postoperative recurrence for which surgery or curative radiation is not possible. *Lung Cancer Treatment Regulations (April 2021 [8th Edition, Revised]) Japan Lung Cancer Society/Ed. (2) Cases of recurrence after adjuvant therapy for the treatment of non-small cell lung cancer could be enrolled as long as it is the first treatment after the completion of adjuvant chemotherapy. (3) Patients must be at least 20 years of age at the time of consent. (4) Patients with KRAS active gene mutation (G12C, G12D/S, G12A/V/R, or G13C). (5) Patients who are scheduled to receive combination therapy with chemotherapy, angiogenesis inhibitors, or immune checkpoint inhibitors, including platinum-based agents, in accordance with the latest package insert and the latest guidelines for promoting optimal use of each drug. (6) Written consent has been obtained from the patients after a thorough explanation of the study details has been provided prior to enrollment in this clinical study.
Exclusion criteria
Exclusion criteria: (1) Patients deemed inappropriate by the physician in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival: PFS | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to treatment failure: TTF Overall survival: OS Overall response rate; ORR Disease control rate; DCR Adverse events including immune related adverse events. | — |
Countries
Japan
Contacts
Public ContactMasaki Ishida
University Hospital, Kyoto Prefectural University of Medicine Department of pulmonary medicine
Outcome results
None listed